Oncology Institute Stock Alpha and Beta Analysis
| TOI Stock | USD 1.00 0.01 0.99% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Oncology Institute. It also helps investors analyze the systematic and unsystematic risks associated with investing in Oncology Institute over a specified time horizon. Remember, high Oncology Institute's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Oncology Institute's market risk premium analysis include:
Beta 0.93 | Alpha 2.14 | Risk 10.69 | Sharpe Ratio 0.25 | Expected Return 2.71 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Oncology |
Oncology Institute Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Oncology Institute market risk premium is the additional return an investor will receive from holding Oncology Institute long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oncology Institute. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Oncology Institute's performance over market.| α | 2.14 | β | 0.93 |
Oncology Institute expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Oncology Institute's Buy-and-hold return. Our buy-and-hold chart shows how Oncology Institute performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Oncology Institute Market Price Analysis
Market price analysis indicators help investors to evaluate how Oncology Institute stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Oncology Institute shares will generate the highest return on investment. By understating and applying Oncology Institute stock market price indicators, traders can identify Oncology Institute position entry and exit signals to maximize returns.
Oncology Institute Return and Market Media
The median price of Oncology Institute for the period between Sun, Nov 3, 2024 and Sat, Feb 1, 2025 is 0.28 with a coefficient of variation of 58.82. The daily time series for the period is distributed with a sample standard deviation of 0.19, arithmetic mean of 0.32, and mean deviation of 0.13. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | The Oncology Institute Announces Third Quarter 2024 Earnings Release Date and Conference Call | 11/05/2024 |
2 | SHAREHOLDER ALERT Levi Korsinsky, LLP Notifies Shareholders of an Investigation into The Oncology Institute, Inc. | 11/08/2024 |
3 | Disposition of 117142 shares by Virnich Daniel of Oncology Institute subject to Rule 16b-3 | 11/12/2024 |
4 | The Oncology Institute Reports Third Quarter 2024 Financial Results | 11/13/2024 |
5 | Disposition of 1026 shares by Podnos Yale of Oncology Institute at 0.136 subject to Rule 16b-3 | 11/20/2024 |
6 | Acquisition by Hively Brad of 44000 shares of Oncology Institute subject to Rule 16b-3 | 11/22/2024 |
7 | Acquisition by Hively Brad of 250000 shares of Oncology Institute at 0.17 subject to Rule 16b-3 | 11/26/2024 |
8 | Oncology institute director Brad Hively acquires 50,000 in stock | 12/02/2024 |
9 | Disposition of 1130 shares by Castle Jeremy of Oncology Institute at 0.16 subject to Rule 16b-3 | 12/03/2024 |
10 | Insider Buying The Oncology Institute, Inc. Director Purchases 42,500.00 in Stock | 12/05/2024 |
11 | Disposition of 258 shares by Rob Carter of Oncology Institute at 0.335 subject to Rule 16b-3 | 01/06/2025 |
About Oncology Institute Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Oncology or other stocks. Alpha measures the amount that position in Oncology Institute has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2024 | 2025 (projected) | Dividend Yield | 0.0265 | 0.0235 | Price To Sales Ratio | 0.53 | 0.51 |
Oncology Institute Upcoming Company Events
As portrayed in its financial statements, the presentation of Oncology Institute's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oncology Institute's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Oncology Institute's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Oncology Institute. Please utilize our Beneish M Score to check the likelihood of Oncology Institute's management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Oncology Institute
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Oncology Institute Backtesting, Oncology Institute Valuation, Oncology Institute Correlation, Oncology Institute Hype Analysis, Oncology Institute Volatility, Oncology Institute History and analyze Oncology Institute Performance. For more detail on how to invest in Oncology Stock please use our How to Invest in Oncology Institute guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Oncology Institute technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.